[go: up one dir, main page]

PL3366688T3 - Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy - Google Patents

Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy

Info

Publication number
PL3366688T3
PL3366688T3 PL18165005T PL18165005T PL3366688T3 PL 3366688 T3 PL3366688 T3 PL 3366688T3 PL 18165005 T PL18165005 T PL 18165005T PL 18165005 T PL18165005 T PL 18165005T PL 3366688 T3 PL3366688 T3 PL 3366688T3
Authority
PL
Poland
Prior art keywords
substituted pyrazolopyrimidines
glucocerebrosidase
activators
glucocerebrosidase activators
pyrazolopyrimidines
Prior art date
Application number
PL18165005T
Other languages
English (en)
Inventor
Juan Jose Marugan
Noel Southall
M. Ehud GOLDIN
Samarjit Patnaik
Ellen Sidransky
Omid Motabar
Wendy Westbrook
Wei Zheng
Original Assignee
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The U.S.A. As Represented By The Secretary, Department Of Health And Human Services filed Critical The U.S.A. As Represented By The Secretary, Department Of Health And Human Services
Publication of PL3366688T3 publication Critical patent/PL3366688T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL18165005T 2010-12-08 2011-12-08 Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy PL3366688T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42094610P 2010-12-08 2010-12-08
EP18165005.2A EP3366688B1 (en) 2010-12-08 2011-12-08 Substituted pyrazolopyrimidines as glucocerebrosidase activators
EP11810714.3A EP2649075B1 (en) 2010-12-08 2011-12-08 Substituted pyrazolopyrimidines as glucocerebrosidase activators
PCT/US2011/063928 WO2012078855A1 (en) 2010-12-08 2011-12-08 Substituted pyrazolopyrimidines as glucocerebrosidase activators

Publications (1)

Publication Number Publication Date
PL3366688T3 true PL3366688T3 (pl) 2022-05-23

Family

ID=45498099

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18165005T PL3366688T3 (pl) 2010-12-08 2011-12-08 Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy
PL11810714T PL2649075T3 (pl) 2010-12-08 2011-12-08 Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11810714T PL2649075T3 (pl) 2010-12-08 2011-12-08 Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy

Country Status (24)

Country Link
US (3) US9353117B2 (pl)
EP (2) EP2649075B1 (pl)
JP (1) JP6154746B2 (pl)
KR (1) KR101931224B1 (pl)
CN (1) CN103534255B (pl)
AU (1) AU2011338377B2 (pl)
BR (1) BR112013014242B1 (pl)
CA (1) CA2820362C (pl)
CY (1) CY1125186T1 (pl)
DK (2) DK3366688T3 (pl)
ES (2) ES2681218T3 (pl)
HR (1) HRP20220512T1 (pl)
HU (1) HUE038635T2 (pl)
IL (2) IL226767B (pl)
LT (1) LT3366688T (pl)
MX (2) MX385600B (pl)
PL (2) PL3366688T3 (pl)
PT (2) PT2649075T (pl)
RS (1) RS63320B1 (pl)
RU (1) RU2603637C2 (pl)
SI (2) SI2649075T1 (pl)
TR (1) TR201810523T4 (pl)
WO (1) WO2012078855A1 (pl)
ZA (1) ZA201304215B (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2681218T3 (es) 2010-12-08 2018-09-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Pirazolopirimidinas sustituidas como activadoras de la glucocerebrosidasa
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN103764166B (zh) * 2011-06-22 2017-10-24 通用医疗公司 蛋白质病的治疗
AU2012272898A1 (en) 2011-06-24 2013-04-11 Amgen Inc. TRPM8 antagonists and their use in treatments
AP2013007331A0 (en) 2011-06-24 2013-12-31 Amgen Inc TRPM8 antagonists and their use in treatments
EP2768509B1 (en) * 2011-10-20 2017-03-22 Glaxosmithkline LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
DK3418281T3 (da) 2012-12-07 2020-12-07 Vertex Pharma Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3077397B1 (en) 2013-12-06 2019-09-18 Vertex Pharmaceuticals Inc. 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
WO2015187451A1 (en) 2014-06-05 2015-12-10 Vertex Pharmacetucals Incorporated Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
CN107072987B (zh) 2014-06-17 2020-02-07 沃泰克斯药物股份有限公司 Chk1和atr抑制剂的组合在制备治疗癌症的药物中的用途
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN107108638A (zh) 2014-11-03 2017-08-29 拜耳制药股份公司 哌啶基吡唑并嘧啶酮及其用途
MX394094B (es) 2014-11-06 2025-03-24 Bial R&D Invest S A PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS.
ES2958391T3 (es) 2014-11-06 2024-02-08 Bial R&D Invest S A Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
WO2016073891A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
JP2018522872A (ja) * 2015-07-01 2018-08-16 ノースウェスタン ユニバーシティ 置換４−メチルピロロ［１，２−ａ］ピリミジン−８−カルボキサミド化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
EP3344632A4 (en) * 2015-09-04 2019-03-20 Lysosomal Therapeutics Inc. Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders
WO2017040879A1 (en) * 2015-09-04 2017-03-09 Lysosomal Therapeutics Inc. Thiazolo(3,2-a) pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2017161137A1 (en) * 2016-03-16 2017-09-21 Lysosomal Therapeutics Inc. Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
EP3440080A4 (en) * 2016-04-06 2020-01-22 Lysosomal Therapeutics Inc. PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
MX2018012208A (es) * 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
MX388912B (es) 2016-04-06 2025-03-20 Lysosomal Therapeutics Inc Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
EP3452480A4 (en) * 2016-05-05 2019-11-06 Lysosomal Therapeutics Inc. SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
MX389579B (es) * 2016-05-05 2025-03-20 Bial R&D Invest S A IMIDAZO[1,2-b]PIRIDAZINAS SUSTITUIDAS, IMIDAZO[1,5-b]PIRIDAZINAS SUSTITUIDAS, COMPUESTOS RELACIONADOS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3535273A1 (en) * 2016-11-02 2019-09-11 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
HUE068033T2 (hu) * 2017-07-28 2024-12-28 Takeda Pharmaceuticals Co TYK2 inhibitorok és azok felhasználása
JP2020530000A (ja) 2017-08-02 2020-10-15 ノースウエスタン ユニバーシティ 置換縮合ピリミジン化合物およびその使用
EP3692028B1 (en) 2017-10-06 2023-04-26 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
US11459325B2 (en) 2018-01-31 2022-10-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
US12049466B2 (en) 2018-05-17 2024-07-30 Forma Therapeutics, Inc. Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
US10882865B2 (en) 2018-08-31 2021-01-05 Northwestern University Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity
US11891400B2 (en) 2018-09-10 2024-02-06 Eli Lilly And Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
PT3860989T (pt) 2018-10-05 2023-06-30 Forma Therapeutics Inc Pirrolinas fundidas que atuam como inibidores da protease 30 específica da ubiquitina (usp30)
US11414431B2 (en) * 2018-10-15 2022-08-16 Nimbus Lakshmi, Inc. Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors
AR117177A1 (es) 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
CN115003383B (zh) * 2019-08-21 2024-10-01 斯克里普斯研究学院 干扰素基因刺激物sting的双环激动剂
CN114787135A (zh) 2019-09-17 2022-07-22 比亚尔R&D投资股份公司 经取代的咪唑甲酰胺及其在治疗医学病症中的用途
JP2022549227A (ja) 2019-09-17 2022-11-24 バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ 医学的障害の治療における使用のための置換された飽和および不飽和ｎ－複素環式カルボキサミドおよび関連化合物
JP2022548747A (ja) 2019-09-17 2022-11-21 バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ 酸性セラミダーゼ阻害剤としての置換されたｎ－複素環式カルボキサミド及び医薬としてのその使用
KR20220150880A (ko) * 2019-11-25 2022-11-11 게인 테라퓨틱스 에스에이 아릴 및 헤테로아릴 화합물, 및 갈락토세레브로시다제의 활성 변경과 관련된 병태에서의 치료 용도
AR121251A1 (es) 2020-02-12 2022-05-04 Lilly Co Eli Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037373A2 (en) 2002-10-21 2004-05-06 The Scripps Research Institute CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE
JP2004277337A (ja) 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
EP1615697A2 (en) * 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
ES2402182T3 (es) 2003-11-12 2013-04-29 Amicus Therapeutics Inc. Derivados de hidroxipiperidina para tratar la enfermedad de Gaucher
CA2507348C (en) * 2004-05-13 2013-07-16 The Hospital For Sick Children Real time methylumbelliferone-based assay
ATE396725T1 (de) * 2004-05-14 2008-06-15 Cleveland Clinic Foundation Kleinmolekülige hemmer für mrp1 und andere multiarzneimitteltransporter
ATE383361T1 (de) 2004-06-21 2008-01-15 Hoffmann La Roche Pyrrazolopyrimidinderivate
DE102005007534A1 (de) * 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
WO2006128184A2 (en) 2005-05-20 2006-11-30 Alantos-Pharmaceuticals, Inc. Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
US20070155737A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
ES2376642T3 (es) * 2005-08-15 2012-03-15 F. Hoffmann-La Roche Ag Derivados de piperidina y de piperazina como antagonistas del p2x3.
AU2006304875B2 (en) * 2005-10-21 2013-01-17 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase II (CK2) modulators
KR101071438B1 (ko) * 2005-10-21 2011-10-10 미쓰비시 타나베 파마 코퍼레이션 카나비노이드 수용체 길항제로서의피라졸로[1,5-ａ]피리미딘 화합물
WO2008054947A2 (en) 2006-10-02 2008-05-08 The Brigham And Women's Hospital, Inc. Structure of acid beta-glucosidase and methods for identifying therapeutic agents
US20090275586A1 (en) 2006-10-06 2009-11-05 Kalypsys, Inc. Heterocyclic inhibitors of pde4
AU2007321924A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
WO2008128106A1 (en) 2007-04-13 2008-10-23 Amicus Therapeutics, Inc. Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
WO2008134036A1 (en) 2007-04-27 2008-11-06 Panacos Pharmaceuticals, Inc. ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES
EP2154969B1 (en) 2007-05-16 2015-11-18 The Brigham and Women's Hospital, Inc. Treatment of synucleinopathies
WO2008154207A1 (en) 2007-06-08 2008-12-18 The Burnham Institute For Medical Research Methods and compounds for regulating apoptosis
JP5337405B2 (ja) 2007-09-17 2013-11-06 ザ・ホスピタル・フォー・シック・チルドレン ゴーシェ病の治療方法
WO2009049422A1 (en) 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8119637B2 (en) * 2008-06-10 2012-02-21 Plexxikon Inc. Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
CA2729766A1 (en) * 2008-07-01 2010-01-07 Zacharon Pharmaceuticals, Inc. Heparan sulfate inhibitors
WO2010086040A1 (en) * 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
ES2681218T3 (es) * 2010-12-08 2018-09-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Pirazolopirimidinas sustituidas como activadoras de la glucocerebrosidasa
MX394094B (es) * 2014-11-06 2025-03-24 Bial R&D Invest S A PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS.

Also Published As

Publication number Publication date
SI3366688T1 (sl) 2022-07-29
WO2012078855A1 (en) 2012-06-14
US20180263988A1 (en) 2018-09-20
PT3366688T (pt) 2022-05-11
RS63320B1 (sr) 2022-07-29
EP2649075A1 (en) 2013-10-16
PT2649075T (pt) 2018-07-30
EP3366688A1 (en) 2018-08-29
AU2011338377B2 (en) 2016-08-04
EP2649075B1 (en) 2018-04-25
LT3366688T (lt) 2022-05-25
KR20140010012A (ko) 2014-01-23
MX385600B (es) 2025-03-18
BR112013014242B1 (pt) 2022-02-22
BR112013014242A2 (pt) 2018-06-26
US20160346284A1 (en) 2016-12-01
SI2649075T1 (sl) 2018-10-30
US9974789B2 (en) 2018-05-22
IL226767B (en) 2018-06-28
DK3366688T3 (da) 2022-05-02
JP6154746B2 (ja) 2017-06-28
HRP20220512T1 (hr) 2022-05-27
CA2820362A1 (en) 2012-06-14
US9353117B2 (en) 2016-05-31
TR201810523T4 (tr) 2018-08-27
RU2013126094A (ru) 2015-01-20
US20140249145A1 (en) 2014-09-04
CN103534255B (zh) 2016-12-21
ZA201304215B (en) 2014-03-26
ES2912284T3 (es) 2022-05-25
CN103534255A (zh) 2014-01-22
MX2013006462A (es) 2013-10-01
ES2681218T3 (es) 2018-09-12
MX354506B (es) 2018-01-16
PL2649075T3 (pl) 2018-09-28
US10925874B2 (en) 2021-02-23
CA2820362C (en) 2020-03-24
AU2011338377A8 (en) 2015-10-29
DK2649075T3 (en) 2018-07-30
IL259648A (en) 2018-07-31
KR101931224B1 (ko) 2018-12-20
IL259648B (en) 2021-03-25
AU2011338377A1 (en) 2013-07-04
RU2603637C2 (ru) 2016-11-27
HUE038635T2 (hu) 2018-11-28
CY1125186T1 (el) 2024-12-13
JP2013544893A (ja) 2013-12-19
EP3366688B1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
IL259648A (en) Pyrazolopyrimidines are converted as glucoserbrosidase activators
AP3607A (en) Substituted imidazopyridazines
IL222646A0 (en) N3-substituted -n1-sulfonyl-5-fluoropyrimidinone derivatives
LT2534132T (lt) Pakeistieji pirolidin-2-karboksamidai
ZA201209117B (en) Tetrahydro-pyrido-pyrimidine derivatives
EP2534256A4 (en) NEW USES
IL226192A0 (en) Modified sodium-1h-pyrazole-5-oleate
EP2541164A4 (en) COOLER
GB2490849B (en) Di-aspirin derivatives
IL225312A0 (en) New combinations
HUP1000243A2 (en) 8-hidroxy-quinoline derivatives
AU4538P (en) H22 Grevillea juniperina
AU332681S (en) Spindle
GB201008355D0 (en) Solid supports
ZA201209248B (en) Amido-tropane derivatives
IL220983A0 (en) 2-aldoximino-5-fluoropyrimidine derivatives
GB201019442D0 (en) Novel combinations
AU2010900285A0 (en) Sparger